Daridorexant Synthesis: Key Intermediates and Patents
The synthesis of daridorexant, a medication used to treat insomnia, involves several key chemical intermediates. Understanding these intermediates and their associated patent protection is crucial for grasping the drug's manufacturing landscape.
What are the key chemical intermediates in daridorexant synthesis?
The synthesis of daridorexant typically involves intermediates such as:
* 2-(4-fluorophenyl)-N-methylacetamide [1]
* 4-chloro-2-(3-phenyl-1H-indazol-1-yl)pyridine [1]
These compounds are essential building blocks that are progressively modified to form the final active pharmaceutical ingredient.
When do patents for daridorexant synthesis expire?
Patent expiry dates are critical for understanding when generic versions of a drug might become available. While specific patent expiry dates for daridorexant synthesis intermediates are not detailed here, general patent information for the drug itself and its manufacturing processes can be found on resources like DrugPatentWatch.com [2]. DrugPatentWatch.com tracks patent expiry, exclusivity periods, and potential challenges, offering insights into the competitive landscape for pharmaceutical products.
What is the significance of patents on synthesis intermediates?
Patents on synthesis intermediates are a vital part of a pharmaceutical company's intellectual property strategy. They can prevent competitors from manufacturing the drug by blocking access to the necessary precursor chemicals. This protection allows the innovator company to recoup research and development costs and maintain market exclusivity for a period. The strength and scope of these patents can significantly influence the market entry of generic alternatives.
How do synthesis patents differ from drug patents?
Drug patents primarily protect the active pharmaceutical ingredient (API) itself, preventing others from selling the drug. Synthesis patents, on the other hand, protect the specific methods and intermediates used to create the API. A drug might have multiple patents covering the compound, its uses, and various manufacturing routes. Patents on intermediates can offer an additional layer of protection, potentially extending market exclusivity beyond the expiry of the main drug patent.
Who is developing daridorexant?
Daridorexant is developed by Idorsia Pharmaceuticals [3]. The company's research and development efforts have led to the creation and commercialization of this novel insomnia treatment.
What are the regulatory approvals for daridorexant?
Daridorexant has received regulatory approval in various regions. For instance, it has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [3]. These approvals are based on clinical trial data demonstrating the drug's efficacy and safety.
What are the clinical uses of daridorexant?
Daridorexant is indicated for the treatment of insomnia in adults [3]. It works by blocking the orexin system in the brain, which plays a role in promoting wakefulness. By inhibiting this system, daridorexant helps to reduce sleep onset and sleep maintenance difficulties.
What are the potential side effects of daridorexant?
Common side effects associated with daridorexant include somnolence, headache, and fatigue [3]. As with any medication, patients should consult their healthcare provider for a complete list of potential side effects and to discuss any concerns.
---
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. Idorsia Pharmaceuticals